Table S2 from Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations

UID: 11181

Author(s): Adib, Elio, Klonowska, Katarzyna, Giannikou, Krinio, Do, Khanh T., Pruitt-Thompson, Solida, Bhushan, Ketki, Milstein, Matthew I., Hedglin, Jennifer, Kargus, Katherine E.*, Sholl, Lynette M., Tsuji, Junko, Hyman, David M., Sisk, Anne*, Shapiro, Geoffrey I., Vargas Alvarez, Hebert Alberto*, Harding, James J.*, Voss, Martin*, Iyer, Gopakumar Vasudeva*, Kwiatkowski, David J. * MSK affiliated

Description: Description from Figshare:

"Table S2. Demographic and clinical characteristics of 30 cancer patients with mTOR pathway mutations. S2.1. Master table showing a summary of demographic characteristics and clinical outcomes. S2.2. Prior systemic treatment regimens. S2.3. Objective response to everolimus according to RECIST v1.1 criteria. S2.4. Toxicity profile of patients according to CTCAE v4.0."

Subject of Study

Homo sapiens

Subject(s)

Clinical Trial, Phase II

Everolimus

Neoplasms/drug therapy

TOR Serine-Threonine Kinases

Do you have or know of a dataset that should be added to the catalog? Let us know!